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Abstract
During the last two decades, the profusion of HIV research due to the urge to identify new
therapeutic targets has led to a wealth of information on the retroviral replication cycle. However,
while the late stages of the retrovirus life cycle, consisting of virus replication and egress, have been
partly unraveled, the early steps remain largely enigmatic. These early steps consist of a long and
perilous journey from the cell surface to the nucleus where the proviral DNA integrates into the
host genome. Retroviral particles must bind specifically to their target cells, cross the plasma
membrane, reverse-transcribe their RNA genome, while uncoating the cores, find their way to the
nuclear membrane and penetrate into the nucleus to finally dock and integrate into the cellular
genome. Along this journey, retroviruses hijack the cellular machinery, while at the same time
counteracting cellular defenses. Elucidating these mechanisms and identifying which cellular factors
are exploited by the retroviruses and which hinder their life cycle, will certainly lead to the
discovery of new ways to inhibit viral replication and to improve retroviral vectors for gene
transfer. Finally, as proven by many examples in the past, progresses in retrovirology will
undoubtedly also provide some priceless insights into cell biology.
Introduction
The life cycle of retroviruses is arbitrarily divided into two
distinct phases: the early phase refers to the steps of infec-
tion from cell binding to the integration of the viral cDNA
into the cell genome, whereas the late phase begins with
the expression of viral genes and continues through to the
release and maturation of progeny virions (see Figure 1 for
a schematic view of the retroviral life cycle). During the
long journey from the cell surface to the nucleus, retrovi-
ruses will face multiple obstacles, since in addition to
finding a path through the cytoplasm to the nucleus they
have to cross two main barriers, the plasma and nuclear
membranes, whilst at the same time avoiding or counter-
acting cellular defences that can interfere with many of
these steps. The surge in Human Immunodeficiency Virus
(HIV) research in order to identify new therapeutic targets
has led to a better understanding of the retroviral life
cycle. However, in comparison with the later events of ret-
rovirus infection (for a review, see [1,2]), early steps are
still poorly understood (for reviews, see [3,4]).
In the case of HIV entry, for example, while the mecha-
nisms of receptor binding, conformational changes and
fusion appear to be relatively well defined, the involve-
ment of attachment molecules and the importance of
lipid rafts in fusion or in recruitment of coreceptors
remain uncertain. Similarly, though the molecular proc-
ess of reverse transcription is well described, very little is
known about the concurrent uncoating process. One of
the most poorly understood steps is the trafficking of pre-
integration complexes (PICs) from the cell surface to the
vicinity of the nucleus, despite a growing body of
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knowledge arising from the study of other viral models
such as adenoviruses (Ad) [5] or Herpes simplex viruses
(HSV) [6]. Much has been learned regarding nuclear
entry, but the cellular proteins involved are still unknown
and the exact role of each viral component remains con-
troversial [7]. Finally, the molecular mechanisms of inte-
gration, the last event of the early phase of retroviral life
cycle, are now well understood, but the choice of target
site remains mysterious. Thus, while certain of these steps
have been characterized, we are still far from obtaining a
complete picture of these processes.
Fully elucidating the early steps of retrovirus replication is
therefore crucial not only for identifying new antiretrovi-
ral drugs, but also for improving the design of retroviral
vectors for gene therapy. Cellular inhibitors that interfere
with these steps can represent useful tools for better char-
acterizing the molecular processes involved and, in this
respect, the recent discovery of cellular factors that block
the lentiviral cycle at an early stage in primates provides
novel directions for AIDS research [8].
In this review, we will summarise our current understand-
ing of the early steps of the retroviral cycle, focussing par-
ticularly on the most recent and controversial findings in
the field.
Binding
The initial step of the retroviral replicative cycle is the
adsorption of viral particles to the surface of their target
cells (see morphology of different retroviral particles on
Figure 2). It remains unclear whether this binding occurs
through specific interactions, but it is thought that such
attachment usually involves molecules which are distinct
The retroviral life cycle Figure 1
The retroviral life cycle. A schematic view of early and late stages of the retroviral replication cycle is represented. Exam-
ples of cellular factors interfering with early steps are indicated: Lv1/Ref1; CEM15, also known as APOBEC3G (apolipoprotein 
B mRNA-editing enzyme-catalytic polypeptide-like-3G) ; Fv2; Fv1. The question marks indicates the exact step affected by the 
restriction factors has not precisely been determined. Lv1 and Ref1 block incoming particles before reverse-transcription 
whereas Fv1 and Fv2 act at a stage between reverse-transcription and integration. See text for detailed discussion. Abbrevia-
tions: RTC, reverse transcription complex; PIC, pre-integration complex.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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from the viral receptor responsible for the entry process
[9]. For example, the initial binding of Murine Leukemia
Virus (MLV) does not involve a specific interaction
between the envelope glycoprotein (Env) and the receptor
that is required for viral entry [10]. Furthermore, whereas
HIV entry into target cells involves CD4 and a coreceptor
(see below), the early attachment of virions to the cell sur-
face has been attributed to a variety of cell-surface mole-
cules (for a review, see [11]), including heparan sulfate
proteoglycan [12], LFA-1 [13] and nucleolin [14]. As the
affinity of HIV envelope glycoproteins for CD4 is rela-
tively low, especially in the case of primary virus isolates
[15], the existence of other attachment factors may serve
to concentrate the virus on the target cell surface prior to
specific receptor engagement. Indeed, the attachment of
virions to the cell surface appears to be the rate-limiting
step of HIV-1 entry [16]. Heparan sulfates (HS) are highly
sulfated polysaccharides, widely expressed on the surface
of cells and which have been shown to be utilized as cell
surface attachment factors by numerous viruses, bacteria
and parasites (for a review, see [17]). Among retroviruses,
they are believed to be implicated in the attachment of
Human T Cell Leukemia Virus (HTLV) [18], MLV [19] and
HIV-1 [12] to their target cells. However, although the
involvement of HS in HIV-1 attachment has been widely
documented, its exact role remains somewhat controver-
sial (reviewed in [20]). It is interesting to note that even
retrovirus-like particles lacking envelope proteins are able
to bind cells via interactions with HS [21], confirming that
the initial attachment of retroviruses to cells is, at least to
a certain extent, Env-independent. However, it is known
that Env-independent and/or receptor-independent bind-
ing of HIV leads to the endocytosis of particles, which is a
dead end with respect to cell infection [22,23].
HIV-1, HIV-2 and Simian Immunodeficiency Virus (SIV)
are known to bind the surface of dendritic cells through
interaction of their envelope glycoproteins with the C-
type mannose binding lectins DC-SIGN (Dendritic cell-
specific intercellular adhesion molecule 3-grabbing non-
integrin) and DC-SIGNR (DC-SIGN related) [24,25].
These molecules cannot be considered as receptors since
they do not promote viral entry leading to productive
infection. Instead, they allow DC to bind and capture viral
particles and should therefore be considered as efficient
binding factors. In the case of HIV-1, it seems that high
mannose structures on gp120 are recognized by DC-SIGN
[26-28], but there may also be a direct interaction
between the two proteins [29]. This interaction allows
HIV particles to use DC as a Trojan horse. Indeed, DCs are
Morphology of budding and mature particles from various retroviruses Figure 2
Morphology of budding and mature particles from various retroviruses. Electron micrographs of retroviral particles 
budding from infected cells (top panel) and of particles after the protease-mediated maturation (bottom panel). Abbreviations: 
MLV, murine leukemia virus; HTLV, human T cell leukemia virus ; HIV, human immunodeficiency virus; FV, foamy virus. Note 
that FV capsid assembly occurs in the cytoplasm similar to B/D typre retroviruses.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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thought to capture virions at peripheral sites of infection
and carry them to the lymph nodes, so promoting
efficient infection in trans of target cells expressing appro-
priate entry receptors [24,25]. But the involvement of den-
dritic cells in lentivirus pathogenesis may be more
complex, since various DC subsets express distinct arrays
of receptors capable of binding HIV gp120 [30].
Interestingly, this strategy seems to be shared by many
other viruses (for a recent review, see [31]) and even by
non-viral pathogens such as Mycobacterium tuberculosis
[32].
Entry
Following the initial step of binding, retroviral particles
use cell-surface proteins as specific receptors to enter their
target cells through interactions with the viral envelope
glycoproteins. As illustrated by the growing list of recep-
tors identified, retroviruses are able to utilize a variety of
cellular proteins to initiate infection, such as the amino-
acid transporter CAT-1 for ecotropic MLV [33,34], the T-
cell surface marker CD4 for HIV [35], the glucose trans-
porter GLUT-1 for HTLV [36] or the phosphate transport-
ers PIT-1 and PIT-2 used by Gibbon ape Leukemia Virus
(GaLV) [37] and amphotropic MLV [38,39], respectively.
In the case of Foamy viruses (FVs), although the receptor
is still unknown, it appears to be ubiquitous since these
retroviruses can infect a very wide range of cell lines,
although CD4+ and CD8+ lymphocytes appear to be the
main in vivo reservoirs [40-42].
Retroviral entry is a complex multi-step mechanism that
has been particularly well studied for HIV. Firstly, the
envelope glycoprotein gp120, present on the surface of
viral particles as gp41/gp120 trimers, recognises the pri-
mary receptor CD4. This interaction leads to conforma-
tional changes in both CD4 and gp120 and to the
recruitment of coreceptors belonging to the chemokine
receptor family, mainly CXCR4 and CCR5 (for a review,
see [43]). A second interaction then takes place between
gp120 and one of these coreceptors, which triggers new
conformational shifts in the envelope glycoproteins [44].
These sequential conformational changes finally lead to
the dissociation of gp120 from gp41, and to the transition
of gp41 to its fusogenic conformation. Entry of virions
into the cell is achieved by insertion of the gp41 fusion
peptide into the target membrane, resulting in the fusion
of viral and cellular membranes and the release of the
viral core in the cytoplasm (for recent reviews, see
[45,46]).
Although it has been suspected for some time that galac-
tosyl ceramide (GalCer) may be used by HIV-1 as an alter-
native receptor to infect neural cells [47], until recently
little else was known about the role of lipids in retroviral
entry. The discovery that lipids are distributed heterogene-
ously within cell membranes has led to the proposal that
sphingolipids and cholesterol tend to segregate into
microdomains called lipid rafts [48]. Several observations
support the hypothesis that lipid rafts may be involved in
the HIV entry process. Firstly, binding of HIV-1 to CD4
has been reported to result in a direct interaction between
gp120 and certain glycosphingolipids in membrane
microdomains [49]. Furthermore, disruption of target cell
membrane rafts by cholesterol depletion prevents HIV-1
infection [50], as does targeting CD4 to non-raft mem-
brane domains [51]. Finally, binding of virus to permis-
sive cells induces the clustering of CD4, CXCR4 and CCR5
within lipid-rafts [50,52,53]. Despite these lines of evi-
dence, the contribution of lipid rafts to HIV entry remains
controversial, as some studies have shown that the locali-
zation of CD4 and CCR5 to non-raft membrane domains
may not prevent HIV entry [54,55]. Interestingly, mem-
brane microdomains also seem to be involved in late
events of the retroviral cycle, since HIV-1 particles have
been found to bud preferentially through raft microdo-
mains of the plasma membrane [56]. This explains the
unusually high cholesterol and sphingomyelin content of
HIV membranes [57], a composition that is thought to be
important for fusion, since cholesterol-depleted virions
fail to enter cells [58].
Most retroviruses, including HIV, enter target cells by
direct fusion with the plasma membrane, as indicated by
their resistance to drugs blocking the acidification of
endosomes [59]. Interestingly, although HIV entry is
strictly pH independent, the majority of viral particles that
bind to the cell surface enters by endocytosis [22]. It seems
that a balance exists between these two entry pathways of
HIV-1 into T-lymphocytes, since the inhibition of one
route increases entry of particles by the alternative mech-
anism [23]. However, particles entering by endocytosis do
not support productive infection as they are degraded by
the proteasome [60], a conclusion supported by the
observation that inhibition of endosomal/lysosomal deg-
radation increases the infectivity of HIV-1 [61]. The only
known exceptions in the retrovirus family are ecotropic
and amphotropic MLV [62], and FVs [63], which seem to
enter target cells by endocytosis, although in the case of
FVs, the possibility of entry by direct fusion cannot be
excluded. However, the route of penetration into the cyto-
plasm can depend of the type of cell being infected.
Indeed, whereas the ecotropic MLV enters mouse NIH 3T3
cells by endocytosis, its entry into rat XC cells occurs by
fusion at the cell surface [64]. It is interesting to note that
the involvement of pH in retroviral entry has been recon-
sidered, since the distinction between pH-dependence
and independence has been shown to be more relative
than initially thought. Indeed, while the entry mechanism
of avian leukosis viruses (ALV) has originally been classi-
fied as pH-independent in comparison to influenza virusRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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(for a review, see [65]), it has been shown to involve a low
pH step [66]. In contrast to influenza virus, it is the
interaction of ALV with its receptor that converts the enve-
lope glycoprotein to a pH-sensitive form, capable of pro-
moting fusion at low pH [66].
Finally, in the case of lentiviruses, there are some exam-
ples of direct infection from cell to cell. This is the case of
dendritic cells which can transmit HIV particles to T-cells
by direct contact without themselves being infected
[25,67,68]. The fact that most of the infectious HIV pro-
duced by primary macrophages is assembled on late
endocytic membranes rather than at the plasma mem-
brane suggests that a direct transmission of virions from
infected macrophages to T-cells during antigen presenta-
tion could also occur [69].
Uncoating and reverse transcription
The fusion of viral and cellular membranes delivers the
viral core into the cytoplasm, where the viral RNA is
reverse transcribed by the virion-packaged reverse tran-
scriptase (RT), generating a linear double-stranded DNA
molecule (for a review, see [70]). Although there is evi-
dence for limited DNA synthesis in virions prior to infec-
tion [71-73], reverse transcription usually occurs after the
release of the viral core into the cytoplasm of the target
cell. The only exceptions are FVs, which also reverse tran-
scribe their RNA during a late stage of their life cycle [74-
76]. Although unique among retroviruses, this feature is
shared with Hepadnaviruses, a viral family that has many
other similarities with FVs (for a review see [77]). The trig-
ger for the initiation of reverse transcription is not clearly
understood, but exposure of the incoming viral ribonucle-
oprotein complex to a significant concentration of deox-
yribonucleotides in the cytoplasm is thought to play an
important role (for a review, see [4]).
Immediately after its release into the cytoplasm, the viral
core undergoes a partial and progressive disassembly,
known as uncoating, that leads to the generation of subvi-
ral particles called reverse-transcription complexes (RTCs)
and pre-integration complexes (PICs). It seems that initi-
ation of reverse transcription is coupled to the onset
uncoating of the viral core [78]. It should be noted that
the distinction between RTCs and PICs is somewhat arbi-
trary, since uncoating is believed to occur progressively,
but PICs are usually defined as the integration-competent
complexes, whereas reverse-transcription is incomplete in
RTCs [79]. Attempts to define the composition of RTCs
and/or PICs have not yielded a clear answer, since the
nature of the viral and cellular components found to be
associated with the viral genome depends on the tech-
nique used for purifying the complexes, which are very
sensitive to detergents. Furthermore, it is known that the
vast majority of viruses entering a cell will not lead to a
productive infection, meaning that purified complexes
may not necessarily represent those particles able to per-
form reverse-transcription, nuclear import or integration.
Indeed, in the case of HIV-1, it has been reported that the
infectivity to particle ratio is as low as 1 in 60,000 [80,81],
even if some mathematical analyses tend to prove that
more than 10% of particles in a viral stock is theoretically
able to infect cells [82].
As a result of these practical restraints, it is still unclear
which proteins remain associated with the viral genome
in the RTCs/PICs. For HIV, RTCs have been shown to asso-
ciate rapidly with the host cytoskeleton after infection,
possibly through a direct interaction between the matrix
protein and the actin network [83]. They appear as large
nucleoprotein structures by electron microscopy and have
a sedimentation velocity of approximately 350 S and a
density of 1.34 g/ml in equilibrium gradients [84,85].
While most studies show that HIV PICs contain protease
(PR), reverse-transcriptase (RT), integrase (IN) and Vpr,
the presence of the structural proteins is more controver-
sial. The capsid proteins (CA) are thought to be released
soon after infection and only trace amounts are found in
PICs. Whereas nucleocapsid (NC) and matrix (MA) were
initially thought to be associated with PICs [86,87], more
recent studies revealed that the majority of these proteins
are lost during the uncoating process [85]. Interestingly, as
some viral structural components are released, certain cel-
lular proteins associate with the PICs during their journey
to the nucleus, such as the high mobility group protein
HMG I(Y), which has been proposed to be important for
integration [88].
It seems that the MLV core persists longer than that of HIV
since NC, MA and CA can all be detected in structures at
the vicinity of the nuclear membrane by electron micros-
copy [89]. However, whereas NC and IN can be detected
in the nucleus, MA and CA were found only in the cyto-
plasm [89,90]. Similarly, in the case of FVs, electron
microscopy studies revealed that incoming capsids seem
to retain an intact structure during their journey from the
cell surface to the microtubule-organizing centre (MTOC)
[91]. Interestingly, FV capsids were never detected either
within the nucleus, or close to nuclear pores, even later
during the replication cycle, whereas unassembled Gag
proteins and the viral genome are detected in the nucleus
early after infection [92]. Therefore, in contrast to viruses
such as Adenovirus type 2 (Ad2) or Herpes Simplex Virus
type 1 (HSV-1), whose capsids dock to the nuclear pore
triggering nuclear translocation of the viral genome [93-
95], nuclear import of FV Gag and genome must be
accompanied by disassembly or significant deformation
of the core particle at the MTOC.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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Some viral and cellular proteins appear to influence the
uncoating and/or the reverse-transcription of retroviruses.
This has been exemplified by HIV-1 Nef and Vif and the
cellular protein cyclophilin A. These three proteins,
present in incoming virions by virtue of their association
with the viral core, have been shown to modulate early
events of the replicative cycle of HIV, but their mode of
action is still unclear. Indeed, viral particles lacking one of
these proteins are less infectious than wild-type and this
defect seems to occur early in the viral cycle. Nef-defective
viruses for example display a strong decrease in infectivity
[96-98]. Since it does not appear to alter virion binding or
entry but does enhance viral DNA synthesis, Nef has been
proposed to act either at the level of viral uncoating or
reverse transcription [99,100]. Nef appears likely to mod-
ulate viral entry only when it occurs by fusion at the
plasma membrane [101], as HIV-1 virions pseudotyped
with the amphotropic MLV envelope [100,102], but not
with the envelope glycoprotein from the vesicular stoma-
titis virus (VSV-G) [100] display Nef-mediated enhance-
ment of infectivity membrane. This mechanism,
dependent on the route used by the virus to enter its target
cell, may be related to the high content of cholesterol
present in the viral particle membrane [57]. Indeed, it has
been proposed that Nef may enhance viral infectivity by
increasing the synthesis and incorporation of cholesterol
into progeny virions [103].
Vif, another HIV-1 accessory protein known to be incor-
porated into virions, also seems to play a role in an early
step of the HIV replicative cycle, as ∆-Vif viruses are unable
to complete viral DNA synthesis [104] and their RTCs are
less stable than wild-type viruses [105]. These observa-
tions may now be explained by recent studies. Indeed, Vif
has been shown to counteract the antiviral activity of
CEM15/APOBEC3G by preventing its incorporation into
progeny virions [106-110]. The fact that this cellular pro-
tein inhibits HIV replication at the step of reverse-tran-
scription is consistent with the observed phenotype of ∆-
Vif viruses. This latter will be discussed in more detail
below.
Finally, the cellular protein cyclophilin A (CypA), which
is incorporated into virions through its interaction with
viral capsid [111-113], has been shown to play a critical
role in the correct disassembly of the HIV-1 cores early
after infection [114], since particles lacking CypA display
a defect between entry and reverse-transcription. How-
ever, these observations are probably due to the failure of
CA to bind CypA rather than the absence of the cellular
protein in the virions. Indeed, some data suggest that
CypA incorporation into virions is dispensable, since
CypA can associate with the CA of incoming particles
within the target cells [115]. CypA is believed to protect
the viral capsid from the human restriction factor Ref1,
leading to an increase in HIV-1 infectivity [115]. The
mechanism of Ref1 restriction will be discussed below.
Additionally, it should be noted that early expression of
viral genes from unintegrated viral cDNA has also been
described [116-120]. Although the role of this early
expression is not clear, it is enhanced in the presence of
Vpr [121].
Trafficking of incoming viruses through the 
cytoplasm
After penetration into the host cell, pathogens have to
reach their sites of replication, the nucleus in the case of
retroviruses. The cytoplasm, containing a high protein
concentration in addition to organelles and the cytoskele-
ton, constitutes a medium in which incoming particles
cannot rely on simple passive diffusion to move. Conse-
quently, viruses have evolved numerous and specific
mechanisms to hijack cellular machinery, and in particu-
lar the cytoskeleton, to facilitate their spread within the
infected cells, [122]. For example, microtubules (MT) are
essential for HSV-1 [6] and Ad [5] to reach the nucleus of
the infected cells, while vaccinia virus exploits first the
microtubule network for its intracellular movement
[123], and then the actin cytoskeleton to enhance its cell-
to-cell spread [124].
Initial studies have revealed that the use of specific drugs
altering the integrity of the cytoskeleton can interfere with
the retroviral cycle, either by directly affecting the intracel-
lular trafficking of incoming viruses or by interfering with
other steps of the early phase of infection such as reverse
transcription. Indeed, it has been shown that an intact
actin cytoskeleton is essential for efficient reverse tran-
scription of HIV-1 [83]. Additional reports have described
specific interactions between retroviral proteins and
cytoskeleton components. For example, HIV-1 IN and NC
have been shown to interact with yeast microtubule-asso-
ciated proteins [125], and actin [126-128], respectively,
but the precise role of such interactions in intracellular
trafficking of incoming viruses remains to be elucidated.
In contrast, several reports have described the effect of ret-
roviral proteins on the cytoskeleton, which might assist
viral replication. This is exemplified by the effect of the
HIV-1 Rev and Vpr proteins on the polymerisation of the
microtubule network [129] or on the nuclear membrane
(see below), respectively, or the ability of Vif to alter the
structure of vimentin network [130]. But once again, a
direct link between these observations and intracellular
trafficking remains to be clarified. Interestingly, the micro-
tubule network has been reported to be implicated in the
intracellular trafficking of incoming retroviruses. Such
movement has been demonstrated for incoming FVs
which target the microtubule organizing centre (MTOC)
prior to nuclear translocation. Centrosomal targeting ofRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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incoming viral proteins and subsequent viral replication
were inhibited by a treatment with nocodazole, demon-
strating the involvement of the MT network in
intracellular trafficking [92]. Remarkably, the Gag protein
by itself can target the MTOC in transfected cells through
interaction with the cytoplasmic light chain 8 (LC8) of the
minus-end directed MT motor dynein [91]. A similar role
for LC8 has been described for ASFV (African Swine Fever
Virus) and rabies virus, two other viruses which use the
MT network to move within infected cells [131-134].
Interestingly, this evolutionarily conserved molecule has
been shown to interact with numerous cellular complexes
such as nitric oxide synthase, or myosin V, an actin-based
motor mainly located at the plasma membrane which
shuttles between the cell periphery and the MTOC along
the MT network (for a review, see [135]). Therefore, inter-
action between incoming retroviral capsids and the multi-
functional LC8 could provide a bridge to shuttle between
an actin-based motor beneath the plasma membrane and
the MT network within the cytoplasm. Remarkably,
McDonald and al. have observed the migration of HIV-1
particles along MT toward the centrosome by following
GFP-tagged viral particles in the cytoplasm of infected
cells. [79]. A MT-dependent movement of retroviral Gag
proteins from the MTOC has also been described during
late stages of the life cycle for HTLV-I [136], the Mason
Pfizer Monkey virus [137,138] and also intracisternal type
A particles [139,140]. Although the viral and cellular pro-
tagonists involved in this transport were not determined,
these observations suggest that distinct classes of retroele-
ments may use the dynein-dynactin complex motor on
the MT network to make their way to or from the nucleus,
through the cytoplasm.
Nuclear entry
The retroviral life cycle requires the integration of the viral
DNA into the host cell genome to form the so-called pro-
virus. To achieve this, the reverse-transcribed DNA associ-
ated with viral proteins to form PICs, must enter the
nucleus (for a review, see [7]). PICs from most retrovi-
ruses are unable to enter intact nuclei and must therefore
"wait" for the breakdown of the nuclear membrane occur-
ring during mitosis [141,142]. Consequently, these retro-
viruses, such as MLV, are dependent on the cell cycle and
cannot replicate in non-dividing cells. In contrast, lentivi-
ruses such as HIV-1 are able to productively infect non-
dividing cells [143], such as macrophages or quiescent T
lymphocytes, indicating that PICs are able to actively cross
the nuclear membrane [144]. Some other retroviruses
seem to have an intermediate capacity to enter the
nucleus, since the PICs of Rous sarcoma virus [145] and
FVs [92,146] are able to penetrate intact nuclei with a low
efficiency, but their replication is dramatically increased
in dividing cells. HIV PICs, composed of the double-
stranded linear DNA associated with the viral proteins
MA, RT, IN and Vpr, have a estimated Stokes diameter of
56 nm [86]. Since the central channel of the nuclear pore
has a maximum diameter of 25 nm and the pore is known
to be able to transport macromolecules up to 39 nm
[147], HIV has developed a strategy to achieve the chal-
lenge of passing through these structures.
Nuclear pore complexes (NPCs) are large supramolecular
protein structures that span the nuclear membrane and
protrude into both cytoplasm and nucleoplasm (for a
recent review, see [148]). Signal-mediated nuclear import
involves the interaction of nuclear localization signals
(NLS) in proteins with nucleocytoplasmic shuttling recep-
tors, belonging to the karyopherin β family, also known as
importins. NLSs are typically short stretches of amino
acids, the best studied of which are basic amino acid-rich
sequences that interact with the receptor importin β,
either directly or through the adapter importin α [148].
Importin β interacts with other classes of NLS using differ-
ent adapters, including snurportin, RIP (for Rev interact-
ing protein), and importin 7. This latter has recently been
proposed to play a key role in nuclear import of HIV-1
PICs in primary macrophages [84]. Four different viral
components have been identified to contribute to the
nuclear import of HIV-1. Among the constituents that are
believed to form the PIC, IN, MA, Vpr and the viral DNA
are suspected to play a significant role in this complex
process, either directly or indirectly, although the exact
function of each remains to be fully understood (for
reviews, see [7,149]).
Integrase has been considered to be the main mediator of
HIV-1 nuclear translocation for some time, but its exact
implication is now being re-evaluated. This viral protein,
which harbours a non-classical NLS, has been shown to
be both necessary and sufficient to promote the nuclear
accumulation of viral PICs [150,151]. The nature of the
pathway used by this NLS is not known, but interestingly,
the nuclear import function of IN was found to be essen-
tial for productive infection of both non-dividing and
dividing cells [151]. This unexpected result suggests that
nuclear entry of HIV-1 PICs during mitosis may not be a
passive process. Supporting this finding, it has been
reported that nuclear import of HIV-1 PICs might be
mitosis-independent in cycling cells [152]. However, new
questions have been raised concerning the karyophilic
properties of IN and the role of its NLS. Indeed, IN has
been found to enter the nucleus even when the NLS has
been mutated [153,154], and some data suggest that
nuclear accumulation of IN does not involve members of
the karyopherinfamily [155]. Furthermore, it has been
proposed that the observed nuclear localization of IN may
result from its ability to bind DNA, in combination to its
degradation in the cytoplasm [156]. Hence, more studiesRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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are required in order to elucidate the exact role of IN in
PIC nuclear import.
Two other HIV-1 proteins have been proposed to possess
karyophilic properties. The first of these is the MA, which
has been found to contain a classical basic NLS in its N-
terminal region (GKKKYK), responsible for targeting the
PIC into the nucleus [157,158]. The mutation of this
signal has been found to block HIV replication in non-
dividing cells [157], whereas it does not interfere with
virus growth in replicating cells [158]. However, the role
of this NLS was later disputed, with several reports dem-
onstrating its dispensability for infection in non-dividing
cells [159-161]. A second NLS has been identified in the
C-terminal region of MA [162], re-igniting the controversy
surrounding the exact role of MA in nuclear import.
The third protein that has been proposed to be involved
in nuclear import of HIV-1 PICs, Vpr [163,164], is proba-
bly the most controversial. This small viral protein (11.7
kD) has been shown to be a component of PICs and,
despite not containing a canonical NLS, various sequences
have been reported to target fusion proteins to NPCs
[165]. Vpr has been found to interact directly with compo-
nents of the NPC, such as importin α [163,166] and
nucleoporin hCG1 [167,168]. These interactions are
believed to enhance nuclear import efficiency [166]. Inter-
estingly, Vpr expression has been shown to induce tran-
sient bulges in the nuclear envelope, which sometimes
burst, creating a channel between the nucleus and the
cytoplasm [169]. However, the precise role of these
nuclear envelope disruptions in PIC nuclear import
remains uncertain, since Vpr-deficient viruses can infect
non-dividing cells efficiently [151,159]. In contrast, the
Vpx protein encoded by HIV-2 and SIV has been shown to
be both necessary and sufficient for the nuclear import of
PICs [170].
Lastly, another component of the HIV-1 PIC that has been
described to be important for nuclear entry is not a pro-
tein but rather an unusual DNA structure present in the
viral DNA of lentiviruses resulting from the reverse tran-
scription mechanism [171]. During this process, the plus
strand DNA is synthesised discontinuously as two halves,
the synthesis of one half being initiated from the central
copy of the polypurine tract sequence (cPPT), whereas the
other starts from the 3' PPT. Consequently, the final prod-
uct is a linear DNA molecule bearing in its centre a stable
99 nucleotide-long plus strand overlap [172], referred to
as the central DNA flap, which has been proposed to act
as a cis-determinant of HIV-1 DNA nuclear import
[171](Figure 3). Zennou et al. have shown that viruses car-
rying a mutated flap are able to complete reverse-tran-
scription but the linear cDNA then accumulates at the
nuclear periphery, instead of entering the nucleus. In con-
trast, the insertion of a central DNA flap into HIV-based
vectors lacking a cPPT dramatically enhances the ability of
these vectors to enter the nucleus of growth-arrested cells
[171,173]. The mechanism by which this triple-stranded
DNA structure acts as an import signal remains unclear.
One possibility could be that the DNA flap induces the
viral DNA to adopt a conformation that permits, or at
least facilitates, its translocation through the nuclear
pores. Alternatively, the DNA flap may be involved in
interactions with cellular proteins such as import cargos
or NPC components. However, other studies showed that
cPPT mutant viruses were still able to replicate efficiently
in both dividing and non-dividing cells [153,174], casting
doubt on the importance of the central DNA flap in HIV-
1 nuclear import. A last report however confirmed the
importance of the DNA FLAP [175] by showing it is nec-
essary and sufficient for efficient HIV-1 single-cycle repli-
cation in both dividing and non-dividing cells [175]. It is
also interesting to note that this structure was implicated
in the integration step of HIV-1 cDNA [173].
In addition to lentiviruses, other retro-elements possess a
cPPT, such as FVs [176,177], the yeast Ty1 retrotranspo-
son [178] and the fish retroviruses Walleye dermal sar-
coma virus (WDSV) [179] and Walleye epidermal
hyperplasia virus (WEHV) [180]. Consequently, the
reverse transcription process in these viruses generates a
cDNA containing a single-stranded gap (Figure 3). How-
ever, the possible implications of this particular structure
in nuclear import of the corresponding PIC have not yet
been investigated. Another issue, which is still debated,
concerns the role of the circular viral DNA forms arising
during the replication cycle of many retroviruses. Firstly,
the so-called 1- or 2-LTR circles, which were initially
thought to be markers of a recent infection and dead-end
complexes, may be in fact stable structures [181]. Further-
more, whereas these circular DNA molecules have been
used as a marker for PIC nuclear translocation and inte-
gration, 2-LTR circles can be detected in the cytoplasm of
MLV infected cells as soon as 2 hours post-viral entry, in
dividing or non-dividing cells [182]. Thus, these different
observations indicate that the exact nature and function of
circular viral DNA must be reconsidered.
Therefore, although several factors were shown to regulate
nuclear import of retroviral genomes in particular in non-
dividing cells, one can bet that future works will precise
the role of each of them and will certainly implicate other
proteins, as recently suggested in the case of HIV-1 CA
[183], in this stage of the replication cycle.
Integration
Although the process of proviral integration has been
intensively studied in in vitro assays in the presence of
recombinant integrase, the molecular basis of in vivo inte-Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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gration of animal retroviruses remains poorly understood.
This unique property of retroviruses maintains the genetic
information life-long in the cell genome and constitutes a
major advantage for retroviral vectors when gene correc-
tion must be continuous. Initially, integration events fol-
lowing the use of retroviral vectors into the host genome
were accepted to be random and the chance of acciden-
tally disruption or deregulated expression of a host gene
was considered to be extremely low. MLV-derived vectors
were used in the first definitive cure of a genetic disease by
gene therapy [184]. Children with SCID-X1 syndrome
recovered a functional immune system following admin-
istration of their own haematopoietic stems cells trans-
duced ex vivo with an MLV vector carrying the γc chain
cytokine receptor gene. Unfortunately, two of the ten chil-
dren developed a leukaemia-like disorder due to the inte-
gration of the retroviral vector near the lmo2 oncogene,
leading to clonal expansion of the corresponding trans-
duced T cells [185,186]. This represents the first descrip-
tion of insertional mutagenesis following a clinical trial of
a murine retroviral vector in humans, raising the old ques-
tion of the potential danger of such viruses, which are
known to cause somatic and germline mutations that lead
to cancers and inherited disorders in their natural hosts.
Indeed, this property of murine leukemia viruses is also
successfully used for the identification of essential cellular
genes involved in tumour development, a technique
called provirus tagging (for a review, see [187]).
Initial studies on retrovirus integration have demon-
strated that proviral insertion generally occurs in a non
sequence-specific fashion but may be influenced by the
A schematic representation of the reverse-transcription process of retroviral RNA Figure 3
A schematic representation of the reverse-transcription process of retroviral RNA. The generation of the central 
DNA FLAP in HIV-1 cDNA and the corresponding gap in the FV cDNA is represented. Abbreviations: PBS, primer-binding site; 
cPPT, central polypurine tract; 3'PPT, 3' polypurine tract; FVs, foamy viruses.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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structure of the neighbouring chromatin [188]. In this
respect, MLV integration was shown to occur within
DNaseI-hypersensitive chromatin regions, suggesting that
actively transcribed genes are preferred targets for provirus
insertion [189], while HIV-1 integration was never
observed in centromeric alphoid repeats [190]. Con-
versely, transcriptionally active regions are not favoured as
sites of integration for ALV [191]. Gaining a global picture
of the integration pattern of a given retrovirus has now
become possible, thanks to the complete sequencing of
the human genome. Schröder et al. have mapped over 500
integration events of HIV-1 and of derived retroviral vec-
tors following infection of a human T cell line, revealing
that integration preferentially occurs in genes highly tran-
scribed by the RNA PolII [192]. This specificity may there-
fore favour efficient HIV-1 gene expression, maximizing
virus propagation whilst being deleterious to host sur-
vival. Similarly, Wu et al. have mapped 903 different inte-
gration sites of MLV, revealing preferential integration
into highly transcribed genes [193]. MLV integration
events distribute evenly upstream and downstream of the
transcriptional start site of actively transcribed genes, +/- 1
kb from the CpG islands, whereas HIV-1 proviruses are
found on the entire length of the transcriptional unit.
Such regional preferences along the host genome, in the
absence of sequence specificity, suggest that integration
may be influenced by specific interaction occurring
between host proteins and viral components or by specific
chromatin architecture in these regions.
Several studies have suggested that the integrase is a key
factor in determining the site of integration and, in this
respect, it is interesting to note that this protein can dock
to mitotic chromosomes in the absence of other viral pro-
teins or viral genome [194-196]. IN, which is a member of
the D, D(35)E transposase/IN superfamily of proteins,
mediates integration of the viral DNA into the host
genome [197]. We know for example that the integrase of
FIV, HIV and Visna virus display distinct preference of
integration sites when given an identical DNA target in
vitro [198-200]. In the case of HIV-1, several cellular DNA
binding proteins have been described to interact with the
integrase and may therefore constitute good candidates
for directing the PIC to its target site. The integrase inter-
actor 1 (Ini1, also called hSNF5), a subunit of the SWI/
SNF chromatin-remodeling complex, was initially iso-
lated by a yeast two hybrid screen for human proteins
interacting with the IN [201] and was proposed to stimu-
late the in vitro DNA-joining activity of the IN and to target
the viral genome to active genes in an as yet undetermined
manner. Equally, HMG-I(Y) [88], a non-histone chromo-
somal protein important for transcriptional control and
chromosome architecture, and the barrier-to-autointegra-
tion factor (BAF) [202], a cellular protein involved in the
reorganization of post-mitotic nuclei, have been identi-
fied as partners of the HIV-1 IN. Both proteins appear to
be required for efficient integration in vitro, but their
respective role in directing the PIC to precise sites of the
host genome was not evaluated.
Two other IN-binding partners were isolated which seem
to be critical for directing the PIC to the host chromatin.
This is the case for the EED protein which is encoded by
the human homologue of the mouse embryonic ectoderm
development (eed) gene product and of the Drosophila esc
gene, and which interacts also with the matrix protein of
HIV-1 [203-205]. These genes belong to the family of
widely conserved Polycomb group of genes, involved in the
maintenance of the silent state of chromatin and reduc-
tion of DNA accessibility. An interaction occurring
between EED and the viral proteins MA and IN might not
only direct the PIC to the host chromatin but also trigger
transcriptional activation [203]. Finally, the lens epithe-
lium-derived growth factor (LEDGF/p75), a protein
implicated in the regulation of gene expression and in the
cellular stress response was found to interact with the
HIV-1 IN [195]. Interestingly, this interaction is not essen-
tial for nuclear accumulation of the HIV-1 IN, but seems
to be absolutely required to dock the PIC to the host chro-
matin ([194] and S. Emiliani, personal communication).
Although the molecular basis of site specificity is unclear
for retroviruses, much more is known about other retrovi-
rus-like elements known to preserve the integrity of the
host genome during their replication. Retrotransposons
contain a similar arrangement of their genes to mamma-
lian retroviruses, and also are flanked by direct repeats
(LTRs), use similar mechanisms to replicate and share
strong reverse transcriptase homologies. However, they
harbour at least two major differences. First, an extracellu-
lar phase of the life cycle is not generally observed in the
case of retrotransposons since most of them do not
encode an envelope glycoprotein. More importantly,
some retrotransposons are non-randomly distributed
along the genome they colonize. This has been evidenced,
for example, by the clustering of retrotransposons in inter-
genic regions of maize [206] or the association of some
retroelements with heterochromatin and telomeres in
Drosophila [207]. The pressure on target site selection is
even more extreme in the case of yeast retrotransposons,
as these elements must integrate their DNA into a gene-
rich, densely packed and timely haploid genome without
disruption of essential host genes. This is the case for Ty1,
a yeast copia-like element, which integrates within a tight
window of 1 to 4 nucleotides upstream of RNA pol III
dependent promoter start sites without deleterious effects
on host survival. Similarly, Ty5, another yeast retrotrans-
posons, specifically inserts into regions of silent chroma-
tin. Such site selection is driven by specific interactions
between the viral integration machinery, especially theRetrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
Page 11 of 20
(page number not for citation purposes)
integrase, and host proteins, allowing a balance between
the fitness of the host and the ability of the
retrotransposon to propagate and survive in the host
genome (for reviews, see [208-210]). A similar mecha-
nism may also account for site selection of animal retrovi-
ruses [211,212].
Understanding the stepwise molecular interactions occur-
ring between cell components and the PIC proteins
responsible for guiding the viral genome to its integration
site will be essential to fully understand the risk factors
and benefits of different retroviral gene-therapy systems.
Moreover, this knowledge is clearly indispensable for the
development of new generations of engineered safer retro-
viral vectors harbouring chosen site specificity. For that
purpose, comparing the specificity of different retroviral
integrases, and other components of the PIC which may
influence chromatin docking, and defining the protein
domains involved in determining site selection will allow
the possibility to engineer this enzyme without loss of in
vivo function. The yeast model has unexpectedly, but sig-
nificantly, improved our understanding of the integration
process regarding animal retroviruses [211,212]. This pro-
vides an excellent system in which to study both the
mechanics of retrotransposon integration and the influ-
ence of host genes, which can affect distinct steps of the
retrotransposon life cycle [213,214]. Indeed, functional
genomics screens for host factors that influence Ty retro-
transposition reveal that several gene products, identified
as host defence factors which are able to limit Ty activity,
were conserved in other organisms [214]. This model will
be useful to provide a starting point for identifying host
factors implicated in retroviral restriction of pathogenic
viruses [215].
Cellular factors interfering with early events of 
retroviral life cycle
While providing all the molecules, proteins and machin-
ery required by viruses to achieve their replicative cycle,
mammalian cells have developed specific defences to pro-
tect themselves against viral infection. Among the array of
antiretroviral genes, some act by interfering with early
steps of the retroviral cycle. However, at the same time,
retroviruses have found strategies to avoid or counteract
many of these host defence mechanisms. For example, the
human apolipoprotein B mRNA-editing enzyme-catalytic
polypeptide-like-3G (APOBEC3G), also known as
CEM15, has recently been reported to be an endogenous
inhibitor of HIV-1 replication [107,110,216]. This cellular
protein is a DNA deaminase that is incorporated into vir-
ions during egress and subsequently exerts antiviral activ-
ity during reverse transcription by triggering G-to-A
hypermutation in the nascent retroviral DNA. It has been
shown that APOBEC3G can inhibit a broad range of retro-
viruses, including HIV, SIV, and MLV, as well as the Hep-
atitis B Virus (HBV), a pararetrovirus whose life cycle also
involves a reverse-transcription step [217]. HIV-1 Vif was
demonstrated to counteract this antiviral protein by pre-
venting the encapsidation of APOBEC3G into virions,
either through inhibition of its expression and packaging
[218,219] or by promoting its degradation by the protea-
some [108,109,220]. The hypermutation of reverse tran-
scripts catalyzed by APOBEC3G may be directly lethal or
may result in instability of the RTCs, consistent with the
described phenotypes of ∆-Vif viruses [104,105].
The search for host genes affecting the susceptibility of
mice to infection by MLV has been particularly extensive,
starting in the early 1970s with the description of a series
of genes controlling responses to Friend virus infection,
known as Fv1-Fv6 (for Friend Virus susceptibility genes 1 to
6). Since then, many other murine genes have been
described affecting the sensitivity of mice to other strains
of MLV. While many of these genes influence the immu-
nological response, others act directly on virus replication
(for a review, see [221]). Most of these latter genes inter-
fere with viral entry by one of two distinct mechanisms.
The first group of genes encodes variant forms of the
receptor used by viruses, such as Slc7a1, an allelic variant
of the ecotropic CAT1 receptor [222] or Svx, a polymor-
phism of the polytropic/xenotropic receptor [223,224].
The second group of resistance factors block MLV entry
through an interference mechanism. The best-character-
ized of these genes, Fv4, expresses high levels of an enve-
lope glycoprotein closely related to that of the ecotropic
MLVs, interfering with receptor binding of exogenous eco-
tropic viruses [225-227]. Another gene, called Rmcf, has
been shown to act by a similar mode of action, and inter-
feres with the binding of polytropic mink cell-focus form-
ing (MCF) MLVs [228,229].
The  Fv1  gene is unique among murine antiviral genes
since it interferes with the replication of MLV at a stage
between reverse-transcription and integration (for
reviews, see [230,231]). There are two major alleles of Fv1
among inbred mice, Fv1n and Fv1b, each displaying a spe-
cific inhibitory activity. MLV strains have been classified
into two groups of tropism, depending which allele of Fv1
blocks their infection: the Fv1n allele, found in NIH Swiss
mice, allows replication of N-tropic but not B-tropic
strains of MLV, whereas Fv1b inhibits MLV N but has no
effect on B viruses (Figure 4). Virus resistance mediated by
Fv1 is semi-dominant in genetic crosses, so that Fv1n/b het-
erozygous animals are resistant to both N- and B-tropic
viruses. The cloning of the Fv1 gene [232] revealed that it
displays a strong sequence similarity (60% of identity
over 1.3 kb) to families of human and murine endog-
enous retroviruses called HERV or MuERV-L, respectively
[233]. Based on its position within the gag  gene,  Fv1
apparently encodes for a CA-like protein.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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While the MLV capsid protein was rapidly suspected to
represent the viral target of Fv1 restriction [234,235], the
restriction specificity has been shown to be mainly deter-
mined by a single amino-acid at position 110 in CA
[236,237]. This latter finding and the fact that Fv1 seems
to be a CA-like protein is consistent with a mechanism in
which Fv1 would interfere with an early event of the MLV
cycle by competing with the capsid of incoming virions.
This is supported by the observation that Fv1 can be satu-
rated by an excess of restricted virus or by the pre-treat-
ment of cells with inactive virion particles, a mechanism
referred to as abrogation [238]. However, the fact that (i)
Fv1 was found to be expressed at extremely low levels, (ii)
is completely unrelated to MLV CA and, (iii) that Gag pro-
teins have never previously been implicated in viral inter-
ference, has led to the suggestion that Fv1 may act via a
more subtle mechanism. So far, this mechanism is still
unknown, but it is believed to involve a direct interaction
between Fv1 and CA [231,239].
Interestingly, similar restriction activities have recently
been described in non-murine cells, and have been shown
to be due to an Fv1-like factor present in these cells (for a
review, see [215]). The first factor, called Ref1 (for Restric-
tion factor 1), interferes with N-MLV and Equine
Infectious Anemia Virus (EIAV) infection in human and
other primate and non-primate species [240-242]. This
factor shows many similarities with its murine counter-
part, and in particular with Fv1b, since it can be abrogated
by an excess of MLV N but not by MLV B [243]. Surpris-
ingly, the same residue 110 in MLV CA that confers the
specificity of inhibition to Fv1 is also responsible for Ref1
specificity [240]. However, Ref1 has been found to act at
a stage between entry and reverse-transcription, whereas
the Fv1 block is subsequent to reverse-transcription [242].
Interestingly, cyclophilin A which is known to be associ-
ated to HIV-1 Gag in virions [112,244] and to facilitate an
early step of infection [114], has been shown to modulate
the sensitivity of HIV-1 to restriction factors [115]. In
human cells, its association with the viral CA prevents it
from being the target of the Ref1 restriction factor,
whereas in certain non-human primates, this association
may be responsible for the restriction of HIV-1 cells by
Ref1 [115]. Surprisingly, the incorporation of CypA into
virions is not a prerequisite for the protection of HIV-1
against Ref1 antiviral activity, as the relevant CA-CypA
interaction takes place in the target cells [115].
The second Fv1-like factor is expressed in certain non-
human primates and, depending on the species, can
inhibit the replication of various lentiviruses, including
N-MLV, HIV-1, HIV-2, SIV and EIAV [245-247]. Because it
shares many characteristics with Fv1, this factor was called
Lv1, for Lentivirus susceptibility 1. Like Fv1 and Ref1, the
viral determinant of Lv1 restriction maps to the viral cap-
sid and, like Ref1, it blocks infection before reverse tran-
scription occurs. The relationship between Fv1, Ref1 and
Lv1 remains to be investigated.
The Fv1 specific inhibition of MLV infection Figure 4
The Fv1 specific inhibition of MLV infection. There are two major alleles of the gene Fv1 among inbred mice, Fv1n and 
Fv1b. Mice that carry the Fv1n allele are protected from B-tropic MLV infection (MLV B), whereas those carrying the Fv1n allele 
cannot be infected by N-tropic strains (MLV N). See text for detailed discussion. Abbreviations: MLV, murine leukemia virus.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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It is likely that the list of genes influencing restriction of
lentiviruses in mammals will grow, as did the series of
genes controlling the sensitivity of mice to Friend virus
infection in the 1970s [248] (Table 1). A restriction factor
interfering with the replication of HIV-2 in certain human
cells has been described [248,249]. This new factor, called
Lv2, which interferes with a step of the HIV-2 life cycle
between the reverse transcription and nuclear entry, is
believed to be unrelated to Fv1, Ref1 and Lv1 [248]. Both
Env and Gag have been found to be viral determinants of
Lv2 activity, the residue 207 in CA being responsible for
the Gag restriction whereas the Env-mediated block is due
to a single amino-acid in gp120 [248]. Recently,
Sodroski's group has identified a protein in rhesus mon-
key that restricts HIV-1 replication [250]. This protein,
named TRIM5  belongs to the tripartite motif (TRIM)
family harbouring a RING domain, one or two B boxes
and a coiled-coil region. Although rhesus TRIM5α dis-
plays Lv1 activity, whether other TRIM proteins also play
a role in the restriction mechanism remains to be
answered. Interestingly, PML, another member of this
protein family, also known as RBCC (for RING domain, B
box, Coiled-Coil), has been shown to limit replication of
certain RNA and DNA viruses (for a review, see [251]).
Finally, among the many questions that remain to be
addressed, it would be interesting to investigate if some
TRIM proteins are involved in Fv1 and Ref1 restriction.
All these results illustrate the striking ability of retrovi-
ruses to counteract the antiviral mechanisms developed
by their hosts, either by direct use of a viral protein, or by
hijacking a cellular factor, thus allowing early steps of the
replicative cycle to proceed.
It is interesting to note that the FV accessory protein Bet
seems to display a similar activity to the cellular restriction
factors described above. This protein is translated from a
multispliced mRNA transcribed from an internal pro-
moter (IP) located between the env gene and the 3' LTR
[252], which also encodes for Tas, the transactivator of
gene expression from both the 5' LTR and the IP. Bet is
highly expressed in infected cells, where it localizes to
both the cytoplasm and the nucleus [253]. Interestingly,
Bet has also been shown to be secreted by infected cells,
and to be internalised by surrounding naive cells [254]
where it targets the nucleus through its C-terminal bipar-
tite NLS [253]. Finally, this protein is believed to be impli-
cated in the establishment and/or maintenance of viral
persistence  in vivo. Indeed, a Tas-defective genome
(∆HFV) has been described to behave like a defective
interfering virus and to interfere with the replication of
wild-type viruses by the production of Bet [255]. Further-
more, expression of Bet has been shown to interfere with
an early stage of FV replication, between virus entry and
integration [256]. The capacity of Bet to prevent up-regu-
lation of basal IP activity might also be a factor in its abil-
ity to block superinfection of cells [257]. Although its role
and mechanism of action are still unclear, these observa-
tions suggest that Bet may help FVs to control their own
spread in order to persist in their host. This protein there-
fore represents an atypical inhibitor of early steps of the
retrovirus replicative cycle.
Perspectives
The stepwise events allowing retroviruses to enter the tar-
get cell, to move within the cytoplasm, to penetrate into
the nucleus and to integrate its genome into host chromo-
somes, are beginning to be unravelled, but many issues
are still unanswered. This is particularly evident concern-
ing the uncoating of incoming viruses, a complex process
involving cellular and viral proteins and which takes place
all along this early journey. It is interesting to note that
among the PIC proteins the viral protease, which is critical
for the late phase of infection, could also be involved in
the uncoating process, as already described for certain ret-
roviruses [258-260] and other viral families [261].
Table 1: Examples of cellular factors inhibiting early steps of retroviral cycle.
Restricted 
Retrovirusesa
Step being 
affectedb
Viral determinantc Distribution Cloned
CEM15 HIV-1 RT Vif human yes
Fv1 N-MLV or B-MLV between RT and 
integration
CA Mouse yes
Ref1 N-MLV, EIAV between entry and RT CA various mammals yes*
Lv1 N-MLV, HIV-1, HIV-2, 
SIVmac, EIAV
between entry and RT CA various mammals yes
Lv2 HIV-2 between RT and 
nuclear entry
CA / Env human no
Abbreviations: a HIV-1, human immunodeficiency virus type 1 ; HIV-2, human immunodeficiency virus type 2 ; SIVmac, simian immunodeficiency 
virus macaques ; N-MLV, N-tropic murine leukemia virus ; B-MLV, B-tropic murine leukemia virus ; EIAV, equine infectious anemia virus. b RT, 
reverse-transcription. c CA, capsid protein ; Env, envelope glycoproteins. *Personal communications and unpublished data.Retrovirology 2004, 1 http://www.retrovirology.com/content/1/1/9
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Similarly, post-translational modifications of viral com-
ponents such as phosphorylation, ubiquitination and/or
sumoylation, could also influence and regulate these early
steps. The way in which retroviruses activate signalling
cascades [262] which might also regulate the behaviour of
the incoming viral components, is still unknown. How-
ever, it has already been demonstrated that HIV-1 virions
hijack many cellular proteins harbouring signalling prop-
erties such as CypA or mitogen-activated protein kinase,
two pivotal proteins known to be implicated in signalling
pathways (for a review, see [263]). An apparent block in
HIV-1 replication was described in resting CD4+ T cells
prior to the integration of the viral genome into host cell
chromosomes in a state called preintegration latency,
awaiting stimulation and a transition to productive infec-
tion. Several studies have demonstrated that resting CD4+
T cells isolated from the blood of HIV-1-infected individ-
uals contain completely reverse transcribed unintegrated
viral DNA, likely constituting a latent reservoir (for
reviews, see [264,265]), since these forms of DNA were
shown to be transcriptionally active [120]. Therefore, it
will also be important to precisely define the intracellular
compartments in which these unintegrated viral structures
localize and how they are maintained. The fact that 2-LTR
junctions can be detected in the cytoplasm of MLV
infected cells soon after viral entry, whereas these struc-
tures were believed to appear in the nucleus only if inte-
gration had occurred [182], may provide a clue to unravel
this unknown mechanism.
Interestingly, the discovery of host gene products that can
interfere with early steps of retroviral infection has
strengthen the idea that the incoming virus is not simply
an inert cage protecting the viral genome but rather inter-
acts widely with cellular components. The identification
of restriction factors and the characterization of their
mode of action may lead to new approaches for blocking
retroviral replication.
Understanding the precise interactions between cellular
and viral partners occurring during the early steps of infec-
tion will certainly open new fields of research leading to
the discovery of new antiretroviral drugs. Towards this
goal, the study of retroelements from distinct organisms,
such as retrotransposons in the yeast model, will help us
to define conserved and non-conserved cellular mecha-
nisms involved in the early steps of infection. This will
also allow the development of safer therapeutic long-term
expression vectors, targeting the transgene to specific
regions of the host genome without deleterious effects
[210,211]. Finally, one can also assume that the study of
early steps of infection will certainly contribute to a better
understanding of principal cell functions.
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